JLL and Water Street Acquire Triplefin
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, and JLL Partners, have acquired Triplefin. An industry leader in patient support for more than 30 years, Triplefin is the latest company to join the investment firms' growing life sciences commercialization services platform.
The addition of Triplefin to the life sciences platform will significantly expand the platform's patient-centered capabilities. Headquartered in Cincinnati, OH, Triplefin specializes in pharmaceutical hub services, including its Hub-Lite and co-pay programs which are dedicated to improving the patient experience. The company's suite of digital capabilities, including its Rx365 technologies, coupled with its customer service services, provides patients with personalized support to enhance their therapeutic success.
"We are thrilled to add this fast-growing, customer-focused business to our platform," said Jim Lang, executive chairman of the platform. "Triplefin brings to us a powerful combination of innovative solutions. Our platform now offers customers end-to-end, best-in-class solutions that will help them successfully engage with every major constituent-regulators, payers, providers, channel partners and patients-to maximize the impact of new therapies. The era of value-based, patient-centered solutions has come, and we aspire to be the industry's partner of choice."
Triplefin follows the platform's recent acquisitions of Dohmen Life Science Services in March, as well as The Access Group, Health Strategies Group and Alliance Life Sciences over the past 18 months. Together, these businesses will offer customers a portfolio of solutions, including channel, market access, patient support and compliance to improve the speed and success of bringing complex therapies to market. As one entity, the newly expanded platform will employ nearly 1,500 global professionals who will serve more than 300 of the industry's top biopharmaceutical and medical device companies.
"These are truly exciting times for Triplefin as we continue to experience unparalleled growth," said Sandy Piscitello, president, Triplefin. "Now, we move toward our next step of joining forces with Water Street and JLL's life sciences platform to strengthen our position in the marketplace and bring our clients an exceptional portfolio of commercialization solutions."
Dale Smith, chairman and chief executive officer of Triplefin's current owner, H. D. Smith Holding Company, said, "We have been proud owners of Triplefin for the past five years and are excited to see the company enter its next chapter. We chose JLL and Water Street as the best partners for Triplefin based on their strong track record of building market-leading companies that put employees and customers first."
Triplefin will continue to operate under its existing name and management team. Sandy Piscitello will continue to lead Triplefin and report to Mr. Lang. The acquisition is expected to close by the end of the second quarter. Financial details are not being disclosed.
Looking for chemical products? Let suppliers reach out to you!
Heritage Pharma Makes Leadership Changes
2026-06-27
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Another big license from Jun Shi. How does Tripley widen the sea road?
-
P&G launched the first major group acquisition in 2023
-
Rainbow acquires S.A. to accelerate market expansion in the EU
-
China丨Grand Holding acquired Microbe with ¥ 830 million to lay out for biopesticide industry chain
-
China丨Maxunitech acquired Shijie, became the tops in Sulfentrazone, Flumioxazin technical production capacity
-
China丨Flagchem acquired 100% equity of Suke to improve its formulation capacity
-
Valued at $110 Million! Zai Lab Partner Entasis Acquired
-
Tuoqiu Shares Acquired 51% Equity of Liaoning Futuo for 30 Million Yuan
-
14.3 Billion Acquisition! Where Will The Chemical Industry Leader 'Transform' in The Future?
-
ExxonMobil Acquires American Materials Company Materia
Recommend Reading
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
The FDA Officially Blesses AI for Liver Drug Development
-
October Aniline Market Stably Rises in China
-
October Activated Carbon Prices First Rise, Then Fall
-
Novoloop Raises 21 Million to Scale Lifecycling Technology and Expand Global Reach
-
Libya and Turkey Sign MoU for 10000 km Offshore Exploration Program
-
Siemens to Close Ontario Factory by 2027 Shifts Production to Concord